Stereotaxis Emerging Digital, AI and Automation Capabilities to be Featured at Heart Rhythm Society’s HRX 2026

Stereotaxis will highlight its FDA-cleared Synchrony system and SynX cloud platform at HRX 2026 focused on AI and automation in EP.

Rhea-AI Summary

Stereotaxis (STXS) will showcase its digital and robotic technologies at Heart Rhythm Society’s HRX conference in Atlanta on September 18-20, 2026.

The company will feature Synchrony, an integrated lab display, and SynX, a cloud-based connectivity platform, alongside discussions and hands-on experiences on the future of cardiovascular care. Chairman and CEO David Fischel will join the main-stage panel “Autonomous and Assistive EP Procedural Systems” on September 19 at 11:35 a.m. EDT to discuss autonomous EP technologies. Synchrony, which received FDA clearance earlier in 2026, is already in use at multiple clinical sites in the US and Europe and is provided with SynX for secure remote collaboration, recording and monitoring.

Key Terms

artificial intelligence, electrophysiology, fda clearance, hipaa, +1 more

5 terms

artificial intelligence technical

"advances in connectivity, artificial intelligence and automation"

Artificial intelligence is the ability of computers and machines to perform tasks that typically require human thinking, such as understanding language, recognizing patterns, or making decisions. For investors, it matters because AI can enhance efficiency, uncover new insights, and enable smarter strategies, potentially impacting the value and performance of companies that develop or utilize this technology.

electrophysiology medical

"in Electrophysiology, Interventional Cardiology, and Neurointerventions"

The study and measurement of the electrical signals that control cells and tissues, most commonly used to diagnose and treat heart rhythm problems and to test how nerves and muscles communicate. Investors care because electrophysiology drives products, procedures and drugs—like monitoring systems, catheter tools and implants—that can alter a medical device or drug maker’s sales, regulatory approvals and clinical trial outcomes; think of it as checking and fixing the wiring that makes the body run.

fda clearance regulatory

"Synchrony received FDA clearance earlier this year"

FDA clearance is the U.S. Food and Drug Administration’s official permission to market certain medical devices or diagnostic tests after reviewing evidence that they are as safe and effective as similar products already on the market. For investors, it’s like a product passing a required safety inspection — it reduces regulatory uncertainty, speeds commercial rollout, and can directly affect sales prospects, valuation, and partnership opportunities.

hipaa regulatory

"a cloud-based HIPAA and GDPR-compliant app"

A U.S. law that sets rules for keeping individuals’ health information private and secure, and for how that information can be shared. Think of it as a mandatory lock-and-key system for medical records that hospitals, insurers, and tech vendors must use. Investors care because failing to follow these rules can lead to big fines, costly remediation, loss of business access to patient data, and reputational damage that can hurt a company’s finances and growth prospects.

gdpr regulatory

"a cloud-based HIPAA and GDPR-compliant app"

General Data Protection Regulation is a law that sets rules for how organizations must collect, store and use personal data about people, and gives individuals rights over that data. It matters to investors because noncompliance can lead to large fines, higher operating costs and damaged reputation, while strong compliance can be a competitive advantage—think of it as a strict safety code for handling customer information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• New digital technologies, including Synchrony and SynX, will be featured at HRX
• Stereotaxis CEO to join main-stage panel on Autonomous EP Systems

ST. LOUIS, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that its portfolio of digital and robotic technologies will be featured at Heart Rhythm Society’s HRX conference, taking place September 18-20, 2026, in Atlanta, Georgia.

Pioneered by the Heart Rhythm Society, HRX brings together clinicians, engineers, and entrepreneurs to explore advances in connectivity, artificial intelligence and automation in cardiovascular medicine. Synchrony, Stereotaxis’ integrated lab display, and SynX, its cloud-based connectivity platform will be among the technologies featured at the conference, along with expert discussions and hands-on experiences focused on the future of cardiovascular care.

Stereotaxis Chairman and CEO, David Fischel, will join a panel of clinical experts on the main stage to discuss the feasibility and potential value of autonomous technologies in the EP lab. The session, “Autonomous and Assistive EP Procedural Systems,” will explore how emerging technologies could improve procedure workflows and expand clinical capabilities. It will take place September 19^th at 11:35 a.m. EDT, will be moderated by Dr. Peter Weiss, and will include physician panelists Dr. Jim Cheung and Dr. Jennifer Silva. Stereotaxis has incorporated initial automation capabilities into its robotic systems and is developing enhanced automation capabilities for catheter and interventional device navigation in Electrophysiology, Interventional Cardiology, and Neurointerventions.

Synchrony received FDA clearance earlier this year and is already in use at multiple clinical sites across the US and Europe. The system consolidates the viewing and control of all disparate systems in the interventional lab, with customizable layouts that allow physicians to organize procedural information around their workflow. Synchrony is made available with SynX, a cloud-based HIPAA and GDPR-compliant app that allows for secure cloud-based connectivity for remote collaboration, recording and monitoring.

“We look forward to participating in HRX and joining the conversation around the future of EP,” said David Fischel. “As robotics, digital technology and AI play an increasingly important role, we are focused on advancing the cutting edge of these technologies as they work together to improve patient care and the physician experience in cardiovascular medicine.”

About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com.

Cautionary Note Regarding Forward-Looking Statements
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, our overall liquidity and our ability to fund operations, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, our ability to manage and integrate recent acquisitions, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and other risks discussed in the Company's periodic and other filings with the SEC. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this press release.

Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Executive Officer

Kimberly Peery
Chief Financial Officer

314-678-6100
Investors@Stereotaxis.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When and with whom will Stereotaxis’ CEO appear on the HRX main-stage panel?

David Fischel will participate in the main-stage session “Autonomous and Assistive EP Procedural Systems” on September 19 at 11:35 a.m. EDT. The panel will be moderated by Dr. Peter Weiss and will include physician panelists Dr. Jim Cheung and Dr. Jennifer Silva.

What capabilities do Synchrony and SynX provide for interventional labs?

Synchrony consolidates viewing and control of disparate interventional lab systems into customizable layouts aligned with physician workflow. It is offered with SynX, a HIPAA- and GDPR-compliant cloud app that supports secure remote collaboration, recording and monitoring.